Pharmaceutical intermediates
Pirtobrutinib Intermediates
4 pharmaceutical intermediates for Pirtobrutinib. Indication: Chronic lymphocytic leukemia; mantle cell lymphoma.
About Pirtobrutinib
- Originator
- Redx Pharma Ltd
- Indication
- Chronic lymphocytic leukemia; mantle cell lymphoma
- Approved Date
- 01/27/2023
- NCE Patent
- 01/27/2028
- DS/DP
- 12/16/2036
Available intermediates
4 intermediates currently listed for Pirtobrutinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| methyl 4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]benzoate | 2182032-85-3 | / | / |
| 4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]benzoic acid | 1571888-11-3 | / | / |
| N-(4-(2,2-dicyanoacetyl)benzyl)-5-fluoro-2- methoxybenzamide | 2819683-07-1 | / | / |
| N-[[4-(2,2-dicyano-1-methoxy-vinyl)phenyl]methyl]-5-fluoro-2-methoxy-benzamide | 2764851-04-7 | / | / |
Building toward Pirtobrutinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →